On February 28, 2023 Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), reported that the board of Isofol has decided to appoint Thomas Andersson as CEO of the company from February 28, 2023 (Press release, Isofol Medical, FEB 28, 2023, View Source [SID1234627849]). As a consequence of this decision, the current CEO, Ulf Jungnelius, is resigning and is now being dismissed from his position.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Thomas Andersson (b. 1952) has long experience from leading positions in the pharmaceutical industry, including as CEO of Spectracure, Senior Advisor at Karolinska Institutet Innovations AB, Investment Manager at Karolinska Development AB, CEO of Lund University Bioscience AB, Head of Cell Therapy at Bavarian Nordic AS and CEO of Annexin Pharmaceuticals AB. He has been part of the founding of more than 15 companies, held over 20 board assignments and is currently Senior Advisor Business Development at Oslo Cancer Cluster Incubator as well as board member of Kongsberg Beam Technology AS, Thepler AS and Skogsmöllan AB. Thomas Andersson has a PhD in physical chemistry from Lund University.
"We are very happy to be able to welcome Thomas Andersson as Isofol’s new CEO. With his extensive experience in company management, drug development and business development, he has excellent background to create value for patients and shareholders based on the company’s drug candidate arfolitixorin," says Mats Franzén, chairman of the board of Isofol Medical AB (publ).
Thomas Andersson succeeds Ulf Jungnelius, who has been CEO of the company since 2019.
For more information, please contact
Isofol Medical AB (publ)
Mats Franzén, Chairman of the Board
E-mail: [email protected]
Phone: +46 (0) 704 47 29 09
This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.45 CET on February 28, 2023.